Biotech , cancer , Drugs Luke Timmerman wrote:Seattle-based Dendreon (NASDAQ: DNDN ), the developer of what it hopes will be the first FDA-approved treatment to actively stimulate the
immune system against cancer, said today the U.S. regulatory agency ...
[Xconomy - 11/20/2009]